Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TABLO: Tranexamic Acid to Reduce Blood Loss in Children With Cerebral Palsy Undergoing Hip Surgery
NCT07672158Phase 3Not yet recruiting
- Sponsor
- Murdoch Children's Research Institute
- Start
- Nov 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of tranexamic acid (2 arms), sponsored by Murdoch Children's Research Institute. Primary endpoint: Postoperative haemoglobin mass loss. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
tranexamic acid
Beyond the preview
Go deeper on NCT07672158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07672158.